146 related articles for article (PubMed ID: 30244364)
1. Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Tsuboya A; Fujita KI; Kubota Y; Ishida H; Taki-Takemoto I; Kamei D; Iwai S; Sasaki Y
Int J Clin Oncol; 2019 Feb; 24(2):222-230. PubMed ID: 30244364
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Kanbayashi Y; Ishikawa T; Kanazawa M; Nakajima Y; Tabuchi Y; Kawano R; Yoshioka T; Yoshida N; Hosokawa T; Takayama K; Taguchi T
Med Oncol; 2018 Apr; 35(6):82. PubMed ID: 29705823
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome.
Iihara H; Fujii H; Yoshimi C; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
Cancer Chemother Pharmacol; 2019 Mar; 83(3):393-398. PubMed ID: 30564875
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Shiozawa T; Tadokoro J; Fujiki T; Fujino K; Kakihata K; Masatani S; Morita S; Gemma A; Boku N
Jpn J Clin Oncol; 2013 May; 43(5):483-91. PubMed ID: 23536639
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
6. [Factors Affecting Development of Cholinergic Symptoms after Irinotecan Administration].
Mizukami Y; Okuyama H; Ishikura K; Tamura K
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1087-1091. PubMed ID: 30042278
[TBL] [Abstract][Full Text] [Related]
7. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Dodds HM; Bishop JF; Rivory LP
J Natl Cancer Inst; 1999 Jan; 91(1):91-2. PubMed ID: 9890180
[No Abstract] [Full Text] [Related]
8. Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Cvitkovic E; Marty M; Wasserman E; Cuvier C; Goldwasser F; Misset JL
J Natl Cancer Inst; 1998 Jul; 90(13):1016-7. PubMed ID: 9665154
[No Abstract] [Full Text] [Related]
9. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Tadokoro J; Kakihata K; Shimazaki M; Shiozawa T; Masatani S; Yamaguchi F; Sakata Y; Ariyoshi Y; Fukuoka M
Jpn J Clin Oncol; 2011 Sep; 41(9):1101-11. PubMed ID: 21852251
[TBL] [Abstract][Full Text] [Related]
11. [Survey of Cholinergic Symptoms in Patients with Colorectal Cancer Who Were Receiving Irinotecan Hydrochloride Combination Chemotherapy].
Kurematsu N; Yoshino M; Sasaki N; Tagawa C; Tanaka Y; Kato K
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1619-1623. PubMed ID: 30449850
[TBL] [Abstract][Full Text] [Related]
12. Bradycardia induced by irinotecan: a case report.
Miya T; Fujikawa R; Fukushima J; Nogami H; Koshiishi Y; Goya T
Jpn J Clin Oncol; 1998 Nov; 28(11):709-11. PubMed ID: 9861240
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D; Guchelaar HJ; Gelderblom H
Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
[TBL] [Abstract][Full Text] [Related]
15. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
17. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
Sakamoto T; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Machida N; Todaka A; Tomita H; Tsushima T; Taniguchi H; Hamauchi S
Int J Clin Oncol; 2010 Jun; 15(3):287-93. PubMed ID: 20217447
[TBL] [Abstract][Full Text] [Related]
18. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Xu Q; Ding YY; Song LX; Xu JF
Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
